CEL-SCI Concludes Meeting With U.S. FDA Concerning Multikine's Approval For Head & Neck Cancer
Portfolio Pulse from Happy Mohamed
CEL-SCI Corporation (NYSE:CVM) has concluded a meeting with the U.S. FDA regarding the approval of Multikine for the treatment of head and neck cancer. The FDA acknowledged the need for improved treatments and is open to collaboration with CEL-SCI. The company is also pursuing approval in Europe, the UK, and Canada, with commercialization possibly beginning in 2024 if Health Canada approves the submission. CEL-SCI's CEO highlighted the drug's potential benefits, including a 4-year median survival benefit and complete tumor elimination in some patients within 3 weeks.
July 14, 2023 | 1:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CEL-SCI's meeting with the FDA regarding Multikine's approval was positive, which could potentially lead to the drug's approval and commercialization. This could have a positive impact on the company's stock.
The FDA's positive response to CEL-SCI's Multikine indicates a potential approval of the drug. This approval could lead to increased revenues for the company, which would likely have a positive impact on the company's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100